Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group trial 9402

Journal of Clinical Oncology

Volumn 24, Issue 18, 2006, Pages 2707-2714

  Cairncross, Gregory ^a   Berkey, Brian ^a   Shaw, Edward ^a   Jenkins, Robert ^a   Scheithauer, Bernd ^a   Brachman, David ^a   Buckner, Jan ^a   Fink, Karen ^a   Souhami, Luis ^a   Laperierre, Normand ^a   Mehta, Minesh ^a   Curran, Walter ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; PCV PROTOCOL;

ADULT; ALLELE; ANAPLASTIC CARCINOMA; ANEMIA; ARTICLE; AUTONOMIC NEUROPATHY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ANALYSIS; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; FEMALE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; INTERMETHOD COMPARISON; LIVER DISEASE; LUNG DISEASE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OLIGODENDROGLIOMA; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; THROMBOCYTOPENIA; VOMITING; ADJUVANT CHEMOTHERAPY; AGED; BRAIN TUMOR; CHROMOSOME 1; CHROMOSOME 19; COMPARATIVE STUDY; GENETICS; HETEROZYGOSITY LOSS; MEGAVOLTAGE RADIOTHERAPY; MIDDLE AGED; MULTICENTER STUDY; RADIATION DOSE FRACTIONATION; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DOSE FRACTIONATION; FEMALE; HUMANS; LOMUSTINE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROCARBAZINE; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, HIGH-ENERGY; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 33745575716     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.3414     Document Type: Article

References (23)

1. Reifenberger G, Louis DN: Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111-126, 2003
2. DeAngelis LM: Brain tumors. N Engl J Med 344:114-123, 2001
3. Puduvalli VK, Hashmi M, McAllister LD, et al: Anaplastic oligodendrogliomas: Prognostic factors for tumor recurrence and survival. Oncology 65:259-266, 2003
4. Walker MD, Green SB, Byar DP, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329, 1980
5. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:360-364, 1988
6. Kim L, Hochberg FH, Thornton AF, et al: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85:602-607, 1996
7. Reifenberger J, Reifenberger G, Liu L, et al: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175-1190, 1994
8. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
9. Smith JS, Perry A, Borell TJ, et al: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645, 2000
10. Mackworth N, Fobair P, Prados MD: Quality of life self-reports from 200 brain tumor patients: Comparisons with Karnofsky performance scores. J Neurooncol 14:243-253, 1992
11. Macdonald DR, Cascino TL, Schold SC, et al: Response criteria for phase II studies of malignant glioma. J Clin Oncol 8:1277-1280, 1990
12. Macdonald DR, Gaspar LE, Cairncross JG: Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27:573-574, 1990
13. Cairncross G, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12:2013-2021, 1994
14. van den Bent MJ, Delattre J-Y, Taphoorn MJB, et al: First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. J Clin Oncol 23:114, 2005 (suppl, abstr 1503)
15. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N Engl J Med 352:987-996, 2005
16. Chinot OL, Honore S, Dufour H, et al: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19: 2449-2455, 2001
17. van den Bent MJ, Taphoorn MJB, Brandes AA, et al: Phase II study of first line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for the Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21:2525-2528, 2003
18. Betensky RA, Zlatescu MC, Sasaki H, et al: Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 7:839-845, 2001
19. Thiessen B, Maguire JA, McNeil K, et al: Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: Relationship to outcome and chemosensitivity. J Neurooncol 64: 271-278, 2003
20. Chahlavi A, Kanner A, Peereboom D, et al: Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: Preliminary results. J Neurooncol 61:267-273, 2003
21. Bauman GS, Ino Y, Ueki K, et al: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 48:825-830, 2000
22. van den Bent MJ, Looijenga LHJ, Langenberg K, et al: Chromosomal anomalies in oligodendroglial tumors are correlated to clinical features. Cancer 97:1276-1284, 2003
23. Hoang-Xuan K, Capelle L, Kujas M, et al: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas and oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133-3138, 2004